Peter Filipcik

Dr. Peter Filipcik

Institute of Neuroimmunology, SAS, Bratislava, Slovakia
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2006 in FEBS Letters
Verified
Journal Article
Closed access
NZNorbert Zilka
Norbert Zilka
PFPeter Filipcik
Peter Filipcik
PKPeter Koson
Peter Koson
LFLubica Fialova
Lubica Fialova
RSRostislav Skrabana
Rostislav Skrabana
MNMichal Novak
Michal Novak

1 May 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ZTZhi Tang
Zhi Tang
Erika BereczkiErika Bereczki
Erika Bereczki
HZHaiyan Zhang
Haiyan Zhang
SWShan Wang
Shan Wang
CLChunxia Li
Chunxia Li
JPJin-Jing Pei
Jin-Jing Pei
Previous evidence from post-mortem Alzheimer disease (AD) brains and drug (especially rapamycin)-oriented in vitro and in vivo models implicated an aberrant accumulation of the mammalian target of rapamycin (mTor) in tangle-bearing neurons in AD brains and its role in the formation of abnormally hyperphosphorylated tau. Compelling evidence indicated that the sequential molecular events such as the synthesis and phosphorylation of tau can be regulated through p70 S6 kinase, the well characterized immediate downstream target of mTor. In the present study, we further identified that the active form of mTor per se accumulates in tangle-bearing neurons, particularly those at early stages in AD brains. By using mass spectrometry and Western blotting, we identified three phosphoepitopes of tau directly phosphorylated by mTor. We have developed a variety of stable cell lines with genetic modification of mTor activity using SH-SY5Y neuroblastoma cells as background. In these cellular systems, we not only confirmed the tau phosphorylation sites found in vitro but also found that mTor mediates the synthesis and aggregation of tau, resulting in compromised microtubule stability. Changes of mTor activity cause fluctuation of the level of a battery of tau kinases such as protein kinase A, v-Akt murine thymoma viral oncogene homolog-1, glycogen synthase kinase 3β, cyclin-dependent kinase 5, and tau protein phosphatase 2A. These results implicate mTor in promoting an imbalance of tau homeostasis, a condition required for neurons to maintain physiological function.

29 August 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ZSZuzana Sekeyová
Zuzana Sekeyová
MDMonika Danchenko
Monika Danchenko
PFPeter Filipcik
Peter Filipcik
FPFournier Pierre-Edouard
Fournier Pierre-Edouard
As a result of migrations and globalization, people may face a possible increase in the incidence of central nervous system rickettsial infections (CNS R). These diseases, caused by Rickettsia species and transmitted to humans by arthropod bites, are putatively lethal. However, the diagnosis of CNS R is challenging and often delayed due to their nonspecific clinical presentation and the strict intracellular nature of rickettsiae. Furthermore, transfer of rickettsiae to the brain parenchyma is not yet understood. The aim of this review is to analyze and summarize the features and correlated findings of CNS R in order to focus attention on these intriguing but frequently neglected illnesses. We also incorporated data on CNS infections caused by Rickettsia-related microorganisms.

1 July 2012 in Neurobiology of Aging
Verified
Journal Article
Closed access
PFPeter Filipcik
Peter Filipcik
NZNorbert Zilka
Norbert Zilka
OBOndrej Bugos
Ondrej Bugos
JKJuraj Kucerak
Juraj Kucerak
PKPeter Koson
Peter Koson
MNMichal Novak
Michal Novak

1 February 2001 in Leukemia
Verified
Journal Article
Open access
PDF file
TLT Lion
T Lion
HDH Daxberger
H Daxberger
JDJ Dubovsky
J Dubovsky
PFPeter Filipcik
Peter Filipcik
GFG Fritsch
G Fritsch
HGH Gadner
H Gadner

7 August 2019 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
PWPetronela Weisová
Petronela Weisová
OCOndrej Cehlár
Ondrej Cehlár
RŠRostislav Škrabana
Rostislav Škrabana
MŽMonika Žilková
Monika Žilková
PFPeter Filipcik
Peter Filipcik
MNMichal Novák
Michal Novák
Pathologically altered tau protein is a common denominator of neurodegenerative disorders including Alzheimer’s disease (AD) and other tauopathies. Therefore, promising immunotherapeutic approaches target and eliminate extracellular pathogenic tau species, which are thought to be responsible for seeding and propagation of tau pathology. Tau isoforms in misfolded states can propagate disease pathology in a template-dependent manner, proposed to be mediated by the release and internalization of extracellular tau. Monoclonal antibody DC8E8, binding four highly homologous and independent epitopes in microtubule-binding domain (MTBD) of diseased tau, inhibits tau-tau interaction, discriminates between healthy and pathologically truncated tau and reduces tau pathology in animal model in vivo. Here, we show that DC8E8 antibody acts via extracellular mechanism and does not influence viability and physiological functions of neurons. Importantly, in vitro functional assays showed that DC8E8 recognises pathogenic tau proteins of different size and origin, and potently blocks their entry into neurons. Next, we examined the mechanisms by which mouse antibody DC8E8 and its humanized version AX004 effectively block the neuronal internalization of extracellular AD tau species. We determined a novel mode of action of a therapeutic candidate antibody, which potently inhibits neuronal internalization of AD tau species by masking of epitopes present in MTBD important for interaction with neuron surface Heparan Sulfate Proteoglycans (HSPGs). We show that interference of tau-heparane sulfate interaction with DC8E8 antibody via steric hindrance represents an efficient and important therapeutic approach halting tau propagation.